Janoshik-Certified
Every Batch Third-Party Tested
Latest COAs Available
Research Grade Purity
Research Use Only
Janoshik-Certified
Every Batch Third-Party Tested
Latest COAs Available
Research Grade Purity
Research Use Only
CJC / IPAMORELIN (NO DAC) 10MG
RM210.00
Two-peptide blend · Mod GRF (1-29) + Ipamorelin
A combined GHRH analogue and selective ghrelin mimetic for synergistic growth hormone axis research.
In stock — ships from Malaysia
Description
Description
Key Research Findings
- Synergy is documented in humans — co-administering a GHRH and a GHRP produces greater growth hormone release than either alone. Reported in Journal of Clinical Endocrinology & Metabolism from 1990 onward, and the reason these two peptide classes are supplied together.
- Sustained GH and IGF-1 — 30-day continuous GHRP infusion maintained elevated pulsatile GH and raised IGF-I, IGFBP-3 and IGFBP-5 in humans (Bowers et al., JCEM 2004).
- Ipamorelin — characterised as the first selective growth hormone secretagogue: it releases GH without meaningfully raising cortisol or prolactin (Raun et al., European Journal of Endocrinology, 1998).
- The GHRH backbone — GRF(1-29) is the active core of growth hormone-releasing hormone. As sermorelin it has been used clinically in humans for decades to assess growth hormone deficiency.
Human evidence covers the GHRH and GHRP peptide classes and the parent GRF(1-29) molecule. There are no published human trials of this specific modified, non-DAC pairing. Provided as scientific background only.
Overview
- A single 10 mg lyophilised vial containing two peptides that stimulate growth hormone through separate routes.
- Mod GRF (1-29), also sold as CJC-1295 without DAC — a stabilised version of the active core of natural GHRH.
- Ipamorelin — a five-amino-acid peptide that mimics ghrelin at its receptor.
- The pairing is deliberate: one presses the accelerator, the other releases the brake, and together they produce more GH release than either alone.
- Supplied for laboratory research only.
How It Works
- Mod GRF (1-29) — activates the GHRH receptor on the pituitary, prompting it to synthesise and release growth hormone while keeping the natural pulsing rhythm intact.
- Ipamorelin — activates the ghrelin receptor (GHS-R1a), a completely separate receptor with its own internal signalling route, and also reduces somatostatin, the body’s natural brake on GH release.
- Why together — because the two act on different receptors through different pathways, their effects compound rather than compete.
- Selectivity — Ipamorelin was developed specifically to avoid the cortisol and prolactin rises seen with earlier growth hormone secretagogues.
- No DAC — this is the short-acting form. Without the drug affinity complex it clears in roughly 30 minutes rather than persisting for days, which is why it is dosed to mimic natural pulses.
Research Effects
Human Clinical Trials
GHRH + GHRP Synergy
Greater growth hormone release from co-administration than from either peptide class alone, reported in human studies since 1990.
Human Clinical Trials
Pulsatile GH Release
Elevated pulsatile GH secretion sustained over 30 days of continuous GHRP infusion in humans.
Human Clinical Trials
IGF-1 Production
Raised IGF-I, IGFBP-3 and IGFBP-5 concentrations reported alongside sustained GH elevation.
Lab & Animal Studies
Selective GH Stimulation
Ipamorelin characterised as releasing GH without significant cortisol, prolactin or aldosterone response.
Lab & Animal Studies
Body Composition
Lean mass and adiposity changes investigated in preclinical models of GH axis stimulation.
Lab & Animal Studies
Recovery & Sleep Architecture
Studied in the context of GH secretion patterns, which are highest during slow-wave sleep.
Human Clinical Trials — reported in published human trial dataLab & Animal Studies — laboratory or animal studies only
Amino Acid Sequences
Mod GRF (1-29) — Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg29 amino acids. Four substitutions to the natural GRF(1-29) sequence resist enzymatic breakdown. No drug affinity complex, so it is not albumin-bound and clears quickly.Ipamorelin — Aib-His-D-2-Nal-D-Phe-Lys-NH2Five amino acids, including two unnatural residues that resist degradation.
View the full research library →
Research use only. Sold strictly for research and laboratory use only. Not for human or animal consumption. Not for diagnostic, therapeutic or clinical use. Citations describe research contexts and do not imply approval for human use.
Related products
